Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

Highly selective and potent α4β2 nAChR antagonist inhibits nicotine self-administration and reinstatement in rats.

SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Scaffold Ranking and Positional Scanning Utilized in the Discovery of Nachr-Selective Compounds Suitable for Optimization Studies

Reversal of a Vigilance Decrement in the Aged Rat by Subtype-Selective Nicotinic Ligands

Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies

Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy

The Subtype-Selective Nicotinic Acetylcholine Receptor Positive Allosteric Potentiator 2087101 Differentially Facilitates Neurotransmission in the Brain.

Synthesis of α3β4 Nicotinic Acetylcholine Receptor Modulators Derived from Aristoquinoline that Reduce Reinstatement of Cocaine-Seeking Behavior

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior

High Selectivity Of An Alpha-Conotoxin Lvia Analogue For Alpha 3 Beta 2 Nicotinic Acetylcholine Receptors Is Mediated By Beta 2 Functionally Important Residues

The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices

Inactivation of phosphodiesterase-4B gene in rat nucleus accumbens shell by CRISPR/Cas9 or positive allosteric modulation of the protein affects the motivation to chronically self-administer nicotine

Partial Agonists for Α4β2 Nicotinic Receptors Stimulate Dopaminergic Neuron Firing with Relatively Enhanced Maximal Effects

The Adenosine A2A Receptor Activation in Nucleus Accumbens Suppress Cue-Induced Reinstatement of Propofol Self-administration in Rats

ABT — 418, a Novel Nicotinic Agonist

l-tetrahydropalmatine reduces nicotine self-administration and reinstatement in rats

Blocking α4β2 and α7 nicotinic acetylcholine receptors inhibits the reinstatement of morphine-induced CPP by drug priming in mice

Affinity of Nicotinoids to a Model Nicotinic Acetylcholine Receptor (nAChR) Binding Pocket in the Human Brain

The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats

β2 nAChR Activation on VTA DA Neurons Is Sufficient for Nicotine Reinforcement in Rats